Literature DB >> 15603812

In vitro and in vivo evaluation of differentially demineralized cancellous bone scaffolds combined with human bone marrow stromal cells for tissue engineering.

Joshua R Mauney1, Claude Jaquiéry, Vladimir Volloch, Michael Heberer, Ivan Martin, David L Kaplan.   

Abstract

Mineralized and partially or fully demineralized biomaterials derived from bovine bone matrix were evaluated for their ability to support human bone marrow stromal cell (BMSC) osteogenic differentiation in vitro and bone-forming capacity in vivo in order to assess their potential use in clinical tissue-engineering strategies. BMSCs were either seeded on bone-derived scaffolds and cocultured in direct cell-to-scaffold contact, allowing for the exposure of soluble and insoluble matrix-incorporated factors, or cocultured with the scaffold preparations in a transwell system, exposing them to soluble matrix-incorporated factors alone. Osteoblast-related markers, alkaline phosphatase (ALP) activity and bone sialoprotein (BSP) and osteopontin (OP) mRNA expression were evaluated in BMSCs following 14 days of cocultivation in both systems. The data demonstrate that BMSCs from some donors express significantly higher levels of all osteoblast-related markers following cocultivation in direct cell-to-scaffold contact with mineralized scaffolds in comparison to fully demineralized preparations, while BMSCs from other donors display no significant differences in response to various scaffold preparations. In contrast, BMSCs cocultured independently with soluble matrix-incorporated factors derived from each scaffold preparation displayed significantly lower levels of ALP activity and BSP mRNA expression in comparison to untreated controls, while no significant differences were observed in marker levels between cells cocultured similarly with different biomaterial preparations. In addition, BMSCs were seeded directly on mineralized and partially or fully demineralized biomaterials and implanted in subcutaneous sites of athymic mice for 8 weeks to evaluate their in vivo bone-forming capacity. The ex vivo incorporation of BMSCs into all bone-derived scaffold preparations substantially increased the mean extent and frequency of samples containing de novo bone formation over similar nonseeded controls, as determined by histological and histomorphometrical analysis. No statistically significant differences were observed in the extent or frequency of bone formation between various scaffold preparations seeded with BMSCs from different donors. These results demonstrate that the in vivo osteoinductivity of bone-derived scaffolds can be modulated by ex vivo incorporated BMSCs and the extent of scaffold demineralization plays a significant role in influencing in vitro osteogenic differentiation of BMSCs depending on the coculture system and BMSC donor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15603812     DOI: 10.1016/j.biomaterials.2004.08.020

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  40 in total

1.  In vitro degradation behavior and cytocompatibility of Mg-Zn-Zr alloys.

Authors:  Z G Huan; M A Leeflang; J Zhou; L E Fratila-Apachitei; J Duszczyk
Journal:  J Mater Sci Mater Med       Date:  2010-06-09       Impact factor: 3.896

2.  Spatial regulation of human mesenchymal stem cell differentiation in engineered osteochondral constructs: effects of pre-differentiation, soluble factors and medium perfusion.

Authors:  W L Grayson; S Bhumiratana; P H Grace Chao; C T Hung; G Vunjak-Novakovic
Journal:  Osteoarthritis Cartilage       Date:  2010-02-06       Impact factor: 6.576

3.  Non-invasive characterization of structure and morphology of silk fibroin biomaterials using non-linear microscopy.

Authors:  William L Rice; Shamaraz Firdous; Sharad Gupta; Martin Hunter; Cheryl W P Foo; Yongzhong Wang; Hyeon Joo Kim; David L Kaplan; Irene Georgakoudi
Journal:  Biomaterials       Date:  2008-05       Impact factor: 12.479

4.  Engineering adipose-like tissue in vitro and in vivo utilizing human bone marrow and adipose-derived mesenchymal stem cells with silk fibroin 3D scaffolds.

Authors:  Joshua R Mauney; Trang Nguyen; Kelly Gillen; Carl Kirker-Head; Jeffrey M Gimble; David L Kaplan
Journal:  Biomaterials       Date:  2007-08-31       Impact factor: 12.479

5.  In vitro evaluation of freeze-dried bone allografts combined with platelet rich plasma and human bone marrow stromal cells for tissue engineering.

Authors:  Elisabetta Cenni; Francesca Perut; Gabriela Ciapetti; Lucia Savarino; Dante Dallari; Annarita Cenacchi; Cesare Stagni; Armando Giunti; Pier Maria Fornasari; Nicola Baldini
Journal:  J Mater Sci Mater Med       Date:  2008-07-31       Impact factor: 3.896

6.  Comparison of TGFbR2 down-regulation in expanded HSCs on MBA/DBM scaffolds coated by UCB stromal cells.

Authors:  Zahra Sadat Hashemi; Mehdi Forouzandeh Moghadam; Masoud Soleimani
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-12-25       Impact factor: 2.416

Review 7.  Biomimetic Approaches for Bone Tissue Engineering.

Authors:  Johnathan Ng; Kara Spiller; Jonathan Bernhard; Gordana Vunjak-Novakovic
Journal:  Tissue Eng Part B Rev       Date:  2017-01-18       Impact factor: 6.389

8.  Three-Dimensional Printing of Bone Extracellular Matrix for Craniofacial Regeneration.

Authors:  Ben P Hung; Bilal A Naved; Ethan L Nyberg; Miguel Dias; Christina A Holmes; Jennifer H Elisseeff; Amir H Dorafshar; Warren L Grayson
Journal:  ACS Biomater Sci Eng       Date:  2016-04-18

9.  Passage-affected competitive regulation of osteoprotegerin synthesis and the receptor activator of nuclear factor-kappaB ligand mRNA expression in normal human osteoblasts stimulated by the application of cyclic tensile strain.

Authors:  Akinori Kusumi; Tomomi Kusumi; Jun Miura; Tomonori Tateishi
Journal:  J Bone Miner Metab       Date:  2009-05-19       Impact factor: 2.626

10.  Bone scaffold architecture modulates the development of mineralized bone matrix by human embryonic stem cells.

Authors:  Ivan Marcos-Campos; Darja Marolt; Petros Petridis; Sarindr Bhumiratana; Daniel Schmidt; Gordana Vunjak-Novakovic
Journal:  Biomaterials       Date:  2012-08-16       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.